India approves first dengue vaccine for people aged 4-60 years

Landmark approval for dengue prevention

India has officially approved its first dengue vaccine, QDENGA, for use in individuals aged 4 to 60 years. The decision marks a significant step in the country's fight against a disease that affects lakhs every year.

The vaccine, developed by Japanese pharmaceutical company Takeda, received the green light from the Drug Controller General of India. It will be available in the private market, with pricing and rollout details expected soon.

How the vaccine works

QDENGA is a live-attenuated tetravalent vaccine. It is designed to protect against all four serotypes of the dengue virus. Clinical trials conducted in dengue-endemic countries, including India, showed it reduces hospitalisations by over 80%.

A city-based private university in India conducted the chemical trial for the vaccine. The results supported its safety and efficacy for the approved age group. Officials have not yet confirmed whether the vaccine will be included in the national immunisation programme.

Eligibility and dosage

The vaccine is recommended for people aged 4 to 60 years. It is given as two doses, three months apart. Those who have had a previous dengue infection can also take it, but doctors advise consulting a physician first.

Pregnant or breastfeeding women, and individuals with weakened immune systems, are not eligible. The vaccine does not replace mosquito control measures, experts stress.

Burden of dengue in India

Dengue is a major public health challenge in India. According to the National Vector Borne Disease Control Programme, over 1.5 lakh cases and 300 deaths were reported last year. The actual numbers are believed to be higher due to underreporting.

The monsoon season typically sees a spike in cases. Hospitals in cities like Delhi, Mumbai, and Bengaluru often run out of beds during outbreaks. The vaccine offers a new tool to reduce severe illness and mortality.

What happens next

The vaccine will be available at private hospitals and clinics. Pricing has not been announced, but industry sources suggest it could cost between Rs 2,000 and Rs 3,000 per dose. The government is expected to issue guidelines on its use later this year.

Watch for whether the vaccine gets included in public health campaigns or remains limited to the private sector. Its impact will depend on affordability and awareness among at-risk populations.